Auto-immunity and the gut microbiome in type 1 diabetes: Lessons from rodent and human studies

Best Pract Res Clin Endocrinol Metab. 2021 May;35(3):101544. doi: 10.1016/j.beem.2021.101544. Epub 2021 May 1.

Abstract

Type 1 diabetes (T1D) is an auto-immune disease that destructs insulin-producing pancreatic beta-cells within the islets of Langerhans. The incidence of T1D has tripled over the last decades, while the pathophysiology of the disease is still largely unknown. Currently, there is no cure for T1D. The only treatment option consists of blood-glucose regulation with insulin injections and intensive monitoring of blood glucose levels. In recent years, perturbations in the ecosystem of the gut microbiome also referred to as dysbiosis, have gained interest as a possible contributing factor in the development of T1D. Changes in the microbiome seem to occur before the onset of T1D associated auto-antibodies. Furthermore, rodent studies demonstrate that administering antibiotics at a young age may accelerate the onset of T1D. This review provides an overview of the research performed on the epidemiology, pathophysiology, interventions, and possible treatment options in the field of the gut microbiome and T1D.

Keywords: NOD mice; microbiome; type 1 diabetes; virome.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 1*
  • Ecosystem
  • Gastrointestinal Microbiome*
  • Humans
  • Insulin
  • Rodentia

Substances

  • Insulin